<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
-----------------------
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b), (c) and (d) AND AMENDMENTS THERETO
FILED PURSUANT TO 13d-2
(Amendment No. ________________)1
NEUROBIOLOGICAL TECHNOLOGIES, INC.
-------------------------------------------------------
(Name of Issuer)
COMMON STOCK , PAR VALUE $0.001 PER SHARE
-------------------------------------------------------
(Title of Class of Securities)
00064124W1
-------------------------------------------------------
(CUSIP Number)
AUGUST 3, 1999
-------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
/ / Rule 13d-1(b)
/ X / Rule 13d-1(c)
/ / Rule 13d-1(d)
- -------------------
1 The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall
not be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 or otherwise subject to the liabilities of that section
of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
<PAGE>
<TABLE>
<S> <C> <C> <C> <C>
- ---------------------------------------- -----------------------------------
CUSIP No. 00064124W1 13G Page 2 of 5 Pages
- ---------------------------------------- -----------------------------------
- ---------- ----------------------------------------------------------------------------------------------------------
1.
NAME OF REPORTING PERSON
IRS IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
MERZ + CO. GMBH & CO.
NONE
- ---------- ----------------------------------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) / /
(b) / /
- ---------- ----------------------------------------------------------------------------------------------------------
3. SEC USE ONLY
- ---------- ----------------------------------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
GERMANY
- ---------------------------- ----------------- ---------------------------------- -----------------------------------
Number of Shares 5. SOLE VOTING POWER 650,419
Beneficially Owned By Each
Reporting Person With
----------------- ---------------------------------- -----------------------------------
6. SHARED VOTING POWER NIL
----------------- ---------------------------------- -----------------------------------
7. SOLE DISPOSITIVE POWER 650,419
----------------- ---------------------------------- -----------------------------------
8. SHARED DISPOSITIVE POWER NIL
- ---------- ----------------------------------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
650,419
- ---------- ----------------------------------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
/ /
- ---------- ----------------------------------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
6.2%
- ---------- ----------------------------------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON*
00
- ---------- ----------------------------------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
</TABLE>
<PAGE>
Page 3 of 5
ITEM 1(a). NAME OF ISSUER
Neurobiological Technologies, Inc.
ITEM 1(b). ADDRESS OF ISSUERS' PRINCIPAL EXECUTIVE OFFICES
1387 Marina Way South
Richmond, California 94804
ITEM 2(a). NAME OF PERSONS FILING
Merz + Co. GmbH & Co.
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE
Eckenheimer Landstrasse 100-104
60318 Frankfurt a.M.
Germany
ITEM 2(c). CITIZENSHIP
Germany
ITEM 2(d). TITLE OF CLASS OF SECURITIES
Common Stock
ITEM 2(e). CUSIP NUMBER
00064124W1
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR
2(c), CHECK WHETHER THE PERSON FILING IS A
N.A.
IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(c), CHECK THIS BOX. / X /
ITEM 4. OWNERSHIP
(a) Amount Beneficially Owned: Immediately exercisable right to convert
loans, including interest thereon, into 650,419 shares of Common Stock
(b) Percent of Class: 6.2% (assumes exercise of conversion rights)
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 650,419
(ii) shared power to vote or to direct the vote: 0
(iii) sole power to dispose or to direct the disposition of: 650,419
(iv) shared power to dispose or to direct the disposition of: 0
<PAGE>
Page 4 of 5
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
N.A.
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
N.A.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE
SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
N.A.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
N.A.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
N.A.
ITEM 10. CERTIFICATION
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not held
for the purpose of or with the effect of changing or influencing the control
of the issuer of the securities, and were not acquired and are not held in
connection with or as a participant in any transaction having that purpose or
effect.
<PAGE>
Page 5 of 5
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true, complete
and correct.
Date: August 9, 1999
Merz + Co. GmbH & Co.
/s/ Dr. Peter Mauritz
--------------------------------------
By: Dr. Peter Mauritz
Its:
/s/ H. W. GLAAB
--------------------------------------
By: H. W. GLAAB
Its:
